Overview

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Atomoxetine Hydrochloride
Criteria
Inclusion Criteria:

- Meet criteria for attention-deficit/hyperactivity disorder

- Have voluntarily signed an informed form

- Are between 18 and 60 years of age

- Will use contraceptive methods during the study

- Women must not be pregnant or breast-feeding

- Must be in generally good health

- Are fluent in English

Exclusion Criteria:

- They have a current or past diagnosis of schizoaffective disorder, schizophrenia,
obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
disorder or mental retardation

- They have a current diagnosis of major depressive episode, generalized anxiety
disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically
significant sleep disorder requiring treatment

- They require ongoing treatment or expected treatment with any psychotropic medication,
including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood
stabilizers, nicotine replacement therapies or varenicline

- They require ongoing treatment or expected treatment with Coumadin

- They failed to respond to two or more adequate trials of FDA-approved ADHD medication

- They have taken atomoxetine during the last 3 months

- They have violent, homicidal or suicidal ideation

- They have a significant history of medical diagnoses, seizure disorder, Tourette's
syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding
ADHD

- They have a urine drug screen that is positive for alcohol or drugs of abuse

- They have a history of substance or alcohol disorder during the last 3 months